DISCLAIMER: This link was displayed at 22:27:51 17/10/2021 and expires on 22/10/2021 if printed.

Go to http://testguide.adhb.govt.nz/EGuide/ for more information.

Acute Myeloid Leukaemia Molecular Panel
Also known as : [AML Molecular Panel]

Test performed by: LabPLUS - Dept. Diagnostic Genetics - Molecular Haematology

Specimen Collection

Note: Bone marrow aspirate should be considered as the preferred sample type for AML Molecular panel testing. Peripheral blood can be used in lieu of bone marrow by clinicians should note that the level of circulating blasts may have an impact on the overall sensitivity of the assay.

CPD3 mL CPD Bone Marrow (Preferred)
EDTA3 mL EDTA Bone Marrow
CPD3 mL CPD Blood
Turnaround Time: Between 1 week and 2 weeks
Diagnostic Use and Interpretation

Molecular variants in a number of genes have been detected in blasts from patients with Acute Myeloid Leukaemia (AML). The National Comprehensive Cancer Network guidelines for clinical practice in oncology recommends the molecular testing of FLT3, NPM1 and CEBPA genes in AML patients with a normal karyotype. The presence or absence of mutations in these genes can alter the prognosis and/or recommended treatment of patients with karyotype normal AML.

Contact Information

To contact the Molecular Haematology team please call:

Auckland City Hospital   (09) 307 4949
Lablink   ext 22000
Prof. Peter Browett (Haematologist)     ext 9090-86281
Nikhil Ghallayan (Section Leader)   ext 22006
Molecular Haematology Lab   ext 22005

For more inforamtion about the Molecular Haematology service at LabPLUS:

Molecular Haematology information page

Last updated at 11:48:27 18/03/2021